OncoMatch/Clinical Trials/NCT05333302
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Is NCT05333302 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD19 CAR-T-cells and Tocilizumab for b-cell acute lymphoblastic leukemia.
Treatment: CD19 CAR-T-cells · Tocilizumab — The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
CD19+ relapsed or refractory lymphoblastic leukemia/lymphoma
Prior therapy
Cannot have received: donor lymphocyte transfusion
Exception: allowed if >6 weeks before CAR-T cells infusion
transfusion of donor lymphocyte less than 6 week before CAR-T cells infusion
Lab requirements
Blood counts
T-cells count in peripheral blood >150 cells/µL
Kidney function
serum creatinine level >=3x upper limit of normal for age excluded
Liver function
ALT or AST >=3x upper limit of normal for age excluded
T-cells count in peripheral blood >150 cells/µL; severe hepatic dysfunction: ALT or AST >=3x upper limit of normal for age; renal dysfunction: serum creatinine level >=3x upper limit of normal for age
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify